Your browser doesn't support javascript.
loading
Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.
Ivanov, Ivan; Matafonov, Anton; Sun, Mao-Fu; Cheng, Qiufang; Dickeson, S Kent; Verhamme, Ingrid M; Emsley, Jonas; Gailani, David.
Afiliação
  • Ivanov I; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
  • Matafonov A; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
  • Sun MF; Department of Bioengineering and Organic Chemistry, Tomsk Polytechnic University, Tomsk, Russia; and.
  • Cheng Q; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
  • Dickeson SK; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
  • Verhamme IM; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
  • Emsley J; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN.
  • Gailani D; Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
Blood ; 129(11): 1527-1537, 2017 03 16.
Article em En | MEDLINE | ID: mdl-28069606
When blood is exposed to variety of artificial surfaces and biologic substances, the plasma proteins factor XII (FXII) and prekallikrein undergo reciprocal proteolytic conversion to the proteases αFXIIa and α-kallikrein by a process called contact activation. These enzymes contribute to host-defense responses including coagulation, inflammation, and fibrinolysis. The initiating event in contact activation is debated. To test the hypothesis that single-chain FXII expresses activity that could initiate contact activation, we prepared human FXII variants lacking the Arg353 cleavage site required for conversion to αFXIIa (FXII-R353A), or lacking the 3 known cleavage sites at Arg334, Arg343, and Arg353 (FXII-T, for "triple" mutant), and compared their properties to wild-type αFXIIa. In the absence of a surface, FXII-R353A and FXII-T activate prekallikrein and cleave the tripeptide S-2302, demonstrating proteolytic activity. The activity is several orders of magnitude weaker than that of αFXIIa. Polyphosphate, an inducer of contact activation, enhances PK activation by FXII-T, and facilitates FXII-T activation of FXII and FXI. In plasma, FXII-T and FXII-R353A, but not FXII lacking the active site serine residue (FXII-S544A), shortened the clotting time of FXII-deficient plasma and enhanced thrombin generation in a surface-dependent manner. The effect was not as strong as for wild-type FXII. Our results support a model for induction of contact activation in which activity intrinsic to single-chain FXII initiates αFXIIa and α-kallikrein formation on a surface. αFXIIa, with support from α-kallikrein, subsequently accelerates contact activation and is responsible for the full procoagulant activity of FXII.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coagulação Sanguínea / Fator XII / Proteólise Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Coagulação Sanguínea / Fator XII / Proteólise Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article